September 10-13, 2019

Boston, MA, USA
Twitter logo for website footers 2

2018 Speakers

Expand/Collapse

Ekta Patel
Associate Director, Translational Sciences
Mustang Bio

Adrian Bot
Vice President, Translational Sciences
Kite, a Gilead Company

Armen Mardiros
Senior Scientist
Kite, a Gilead Company

Ian Catchpole
Director of Research
TC Biopharm

James Noble
CEO
Adaptimmune

Day Two

Thursday September 6th 2018

08.30 | Next Generation CAR-TCR Therapies: Executive Leaders’ Fireside Chat

Mark Dudley
Senior Vice President of Bioprocessing
Adaptimmune

Eric Van Hofe
President
AffyImmune Therapeutics

Paul Rennert
President & CSO
Aleta Biotherapeutics

David Chang
CEO
Allogene Therapeutics

Day Two

Thursday September 6th 2018

08.30 | Next Generation CAR-TCR Therapies: Executive Leaders’ Fireside Chat

Jim Faulkner
SVP & Head of Product Delivery
Autolus

Jamie Margolis
Director, Product Development Operation
Be The Match BioTherapies

Peter Olagunju
VP
bluebird bio

Philip Gregory
CSO
bluebird bio

Day Two

Thursday September 6th 2018

08.30 | Next Generation CAR-TCR Therapies: Executive Leaders’ Fireside Chat

Rick Morgan
Vice President of Immunotherapy
bluebird bio

Shawn Foley
Attorney, Intellectual Property
Burns & Levinson

Shawn P. Foley, Esq., is of counsel in Intellectual Property Group at Burns & Levinson, in Boston, MA. In his more than 30 years of experience,  he has gained several perspectives of the patent system.   Mr. Foley began his career as an examiner with the U.S. Patent Office, where he reviewed patent applications during the emergence of the biotechnology field.  As in house counsel, he counseled an AgBio company that was among the pioneering efforts to commercialize transgenic crop seed. Having spent the majority of his career in private practice, Mr. Foley has particularly enjoyed creating commercially valuable patent estates for a variety of clients, and in many different technologies.  He has extensive experience in immunotherapy including CAR technology, chimeric proteins, monoclonal antibodies (including antibody-drug conjugates), industrial enzymes, therapeutic and diagnostic nucleic acids, small molecules and new chemical entities, drug delivery systems,  crop science, and medical devices.   Mr. Foley was named a leader in intellectual property law in the Chambers USA: America's Leading Lawyers for Business guide (2011). He was also recommended in IAM Patent 1000 2015 - The World’s Leading Patent Professionals in the category of patent prosecution.

Andy Philips
CEO
C4 Therapeutics

Jennifer Fillman
Vice President and General Manager, Specialty Services
Cardinal Health Specialty Solutions

Day Two

Thursday September 6th 2018

10.00 | Driving Adoption of Your CAR-T Therapy with a Proven Logistics and Access Strategy

Steven Kelly
President and CEO
CARMA Therapeutics

Zonghai Li
Founder, CEO and CSO
CARSgen Therapeutics

André Choulika
CEO
Cellectis

Day Two

Thursday September 6th 2018

08.30 | Next Generation CAR-TCR Therapies: Executive Leaders’ Fireside Chat

David Sourdive
EVP, Technical Operations
Cellectis

Stefanos Theoharis
SVP, Partnering and Corporate Development
Cell Medica

Benham Badie
Professor & Chief, Division of Neurosurgery & Director
City of Hope Medical Center

Mike Stella
Chief Business Officer and Director
Cognate

Mark Sawicki
Chief Commercial Officer
Cryoport

Charles Sentman

Dartmouth Geisel School of Medicine

Gopalan Narayanan
Vice President
Disruptive Biologics

Dr Narayanan provides leadership in the area of complex and disruptive biologics such as Cell and Gene therapies, including guidance on product development and regulatory strategy and in the global effort of rationalising the development process through which such disruptive biologics can be brought to patients faster and more efficiently. Narayanan was a senior regulator at the UK MHRA for nearly 12 years as an expert medical assessor, and 4 years as Manager of the Biologicals Unit. He was a member of the Committee for Advanced Therapies (EMA/CAT 2009 – 2013), Scientific Advice Working Party (CHMP/SAWP 2009 - 2013) representing  EMA/CAT, Biosimilar Working Party (EMA/BMWP) and Gene Therapy Working Party (CAT/GTWP). Narayanan qualified as a physician, and has dual specialist postgraduate qualification in general internal medicine and pharmaceutical medicine. He is currently on the Scientific Editorial Board of Human Gene Therapy Clinical Development journal and is a Review Editor of Regulatory Science section of Frontiers in Medicine, and is based in the UK.

Chris Leamon
Vice President of Research
Endocyte

Edmund Pezalla
CEO & Founder
Enlightenment Bioconsult LLC

Bijan Nejadnik
CMO
Eureka Therapeutics

Cheng Liu
CEO
Eureka Therapeutics

Bob Valamehr
VP, Cancer Immunotherapy
Fate Therapeutics

Jim Beitel
SVP, Corporate Development
Fate Therapeutics

Richard Grant
Chief Product Officer
FloDesign Sonics

Philip Vanek
GM, Cell Therapy Growth Strategy
GE Healthcare

Day Two

Thursday September 6th 2018

09.30 | Smart, Closed & Connected Solutions for Cell Therapy Production

Robert Preti
CEO & President
Hitachi Chemical Advanced Therapeutics Solutions

Cameron Durrant
Chairman and Chief Executive Officer
Humanigen, Inc.

Eileen Higham
Head of Analytical and Process Development
Juno Therapeutics

Ali Mohamed
VP, CMC
Immatics

Steffen Walter
Co-Founder & CSO
Immatics

Sean MacKay
CEO
Isoplexis

Peter Emtage
Global Head of Cell Therapy
Kite, a Gilead Company

Yuan Xu
CEO
Legend Biotech

Bala Manian
Executive Chairman
LeukoDx

Nina Bauer
Commercial Development Lead, Autologous Cell Therapy
Lonza

Nina Bauer is the Commercial Development Lead of Lonza’s autologous cell therapy business. She is in charge of establishing novel manufacturing technologies to remove bottlenecks and enable commercial services for patient-scale therapies. Prior to joining Lonza, Nina held business development roles at the Cell Therapy Catapult (London), and the University of Edinburgh, and worked as Life Science Consultant for regenerative medicine businesses. She holds a PhD in Neuroscience from the University of Oldenburg (GER), an MBA from the University of Edinburgh (UK), and conducted post-doctoral research at the Weizman Institute (ISR), Salk Institute (USA), and the University of Edinburgh (UK).

Saad Kenderian
Director, T cell Engineering Program
Mayo Clinic

Dolores Schendel
CEO & CSO
Medigene

Isabelle Rivière
Director, Cell Therapy and Cell Engineering Facility
Memorial Sloan Kettering Cancer Center

Boro Dropulic
CSO & General Manager, Lentigen Technology
Miltenyi Biotec Company

Sadik Kassim
Chief Scientific Officer
Mustang Bio

James Kochenderfer
Investigator, Experimental Transplantation & Immunology Branch
National Cancer Institute

Mario Marcondes
Medical Director, Clinical Development
Nektar Therapeutics

Rona Singer Weinberg
Director, Cellular Therapy Laboratory Director, MPD Laboratory
New York Blood Center, Blood Centers of America

Koji Tamada
CSMO
Noile-Immune Biotech

Rodney Rietze
Director, Strategic Development and Innovation, Cell and Gene Therapy Development and Manufacturing
Novartis

Samuele Butera
Global Cell & Gene Therapies Business Leader
Novartis

Day Two

Thursday September 6th 2018

17.15 | Closing Ceremony Panel Discussion: Lessons Learnt from the Leaders

Therese Choquette
Analytical Project Leader, Cell and Gene Therapy Development and Manufacturing
Novartis

Yajin Ni
Director, CART Manufacturing Process Development
Pfizer

Vita Golubovskaya
Director R&D, BD
Promab Biotechnologies

Kent Thorup
Regional Vice President, Business Development
Quick Specialized Healthcare Logistics

Barbra Sasu
VP, Head of Biology & CAR-T Lead
Rinat/Pfizer

Heidi Hagen
Co-founder & CSO
Vineti

Heidi has been an Operations Executive in the Biotechnology industry for over 25 years and is a Co-founder of Vineti. She has an extensive and proven track record in leading operations and commercializing innovative technologies ranging from recombinant protein/device combinations to the first active immune cell therapy, Provenge. Previously, Heidi was the Global COO for SOTIO, in Prague, Czech Republic with a US office in Boston, MA. Before joining SOTIO she worked for Dendreon for ten years as Senior Vice President of Operations and ten years with Immunex Corporation in a range of roles in drug development and operations management. Heidi has a B.S. in Cell and Molecular Biology, an MS in Bioengineering, and an MBA from the University of Washington.  

Gary Lee
Vice President, Cell Therapy
Sangamo Biosciences

Steven Feldman
Director, Manufacturing and Process Development
Stanford School of Medicine

Robert Hofmeister
CSO
TCR2 Therapeutics

Dalip Sethi
Senior Director, Product Development & Validation
ThermoGenesis

John Connolly
Chief Scientific Officer
Tessa Therapeutics

Usman Azam
President & CEO
Tmunity

Day Two

Thursday September 6th 2018

08.30 | Next Generation CAR-TCR Therapies: Executive Leaders’ Fireside Chat

Thomas Andresen
Co-founder and CSO
Torque Therapeutics

Jeffrey Tice
Professor of Medicine, Division of General Internal Medicine
University of California, San Francisco

Avery Posey

University of Pennsylvania

Bruce Levine
Founding Director of the Clinical Cell and Vaccine Production Facility (CVPF)
University of Pennsylvania

Carl June
Professor & Director Translational Research, Abramson Cancer Center
University of Pennsylvania

Day One

Wednesday September 5th 2018

08.15 | Opening Ceremony

David Porter
Director of Cell Therapy and Transplant
University of Pennsylvania

Roderick O’ Connor
Instructor, Center for Cellular Immunotherapies
University of Pennsylvania School of Medicine

Simon Lacey
Director Translational and Correlative Studies Laboratory, Center for Cellular Immunotherapies
University of Pennsylvania

Miguel Forte
Chief Executive Officer
Zelluna Immunotherapy